Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus–positive oropharyngeal squamous cell carcinoma
- 13 October 2015
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 38 (S1) , E1117-E1121
Abstract
Background There is interest in different treatment strategies, including deintensification in good prognosis human papillomavirus‐positive (HPV(+)) oropharyngeal squamous cell carcinoma (SCC). We reviewed our experience with weekly cisplatin in low‐risk, locoregionally advanced HPV(+) oropharyngeal SCC since late 2009. Methods Data from patients with low‐risk HPV(+) oropharyngeal SCC treated with weekly cisplatin (40 mg/m2) and 70 Gy radiotherapy were collected. Low risk was defined as stage III to IV oropharyngeal SCC excluding T1‐2N1, T4 or N3 disease, or N2b to N2c disease in patients with >10 pack‐year smoking history. Results Of 31 patients, the median age was 56 years (range, 41–69 years). All patients completed 70 Gy radiotherapy within 51 days and 84% completed at least 5 cycles of cisplatin. Grade 3 mucositis occurred in 22 patients (71%) and grade 3 febrile neutropenia in 6 patients (19%). No patients required enteral feeding at 12 months. The median follow‐up was 30 months (range, 21–57 months) with no recurrences or deaths. Conclusion Concurrent weekly cisplatin is relatively well‐tolerated and associated with excellent disease control in low‐risk, locoregionally advanced HPV(+) oropharyngeal SCC. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1117–E1121, 2016Keywords
This publication has 20 references indexed in Scilit:
- Controversies in Treatment Deintensification of Human Papillomavirus–Associated Oropharyngeal Carcinomas: Should We, How Should We, and for Whom?Journal of Clinical Oncology, 2013
- Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant MetastasisJournal of Clinical Oncology, 2013
- Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III TrialJournal of Clinical Oncology, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancerCancer, 2010
- Intensity-Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional ResultsJournal of Clinical Oncology, 2010
- Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trialAnnals of Oncology, 2010
- Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: The University of Wisconsin experienceHead & Neck, 2010
- Prioritizing treatment outcomes: Head and neck cancer patients versus nonpatientsHead & Neck, 2004
- An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck CancerJournal of Clinical Oncology, 2003